Answers are grounded in this paper and cite their sources.
Purpose To describe the outcome of a novel combined therapeutic approach encompassing topical insulin eye drops and cross-linked hyaluronic acid canalicular gel in a case of severe recalcitrant neurotrophic keratopathy (NK) complicated by keratolysis. Case Presentation A 52-year-old male presented with a recalcitrant Mackie stage III post-herpetic NK in the right eye, characterized by a large persistent epithelial defect (PED) (area of 49.7 mm 2 ), central stromal melting, corneal anesthesia, and neovascularization. Best-corrected visual acuity (BCVA) was reduced to hand motion. The new therapeutical approach included the withdrawal of previous therapies and the initiation of topical insulin (1 unit/mL, 4 times daily) combined with the insertion in the lower punctum of cross-linked hyaluronic acid canalicular gel (Lacrifill, Nordic Pharma, Inc., Berwyn, PA, US) to enhance ocular surface drug retention. In the subsequent follow-up visits, the PED area progressively decreased to 19.6 mm 2 at 2 weeks and 4.4 mm 2 at 4 weeks; complete re-epithelialization was achieved at 8 weeks. In parallel, BCVA improved to counting fingers at 1 meter. No adverse events were reported. Conclusions The combined use of topical insulin and cross-linked hyaluronic acid canalicular gel allowed achievement of complete corneal healing in a case of severe recalcitrant NK complicated by keratolysis. The regenerative properties of insulin eye drops were enhanced by the concomitant insertion of the occlusive device. This approach represents a rational, accessible, and well-tolerated therapeutic strategy that warrants further investigation in prospective controlled studies.
No takes yet. Share an insight, caveat, or question.
Lixi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: